Patents by Inventor Tze Chein Wun

Tze Chein Wun has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method of stabilizing plasminogen activator inhibitor by treatment with vitronectin
    Patent number: 5112955
    Abstract: A method of purifying PAI-1 from a biological fluid source, e.g. conditioned media of Hep G2 or HT 1020 cells, containing PAI-1 is disclosed, which comprises subjecting the biological fluid to a modified urokinase affinity absorbent, e.g. anhydrourokinase ligand bound to a CNBr-activated agarose gel or urokinase mutated at amino acid position 356 from Ser to Gly and bound to the gel, and then eluting PAI-1 from said affinity absorbent. A method of stabilizing and/or activating PAI-1 is also disclosed, which comprises complexing PAI-1 with vitronectin.
    Type: Grant
    Filed: April 8, 1991
    Date of Patent: May 12, 1992
    Assignee: Monsanto Company
    Inventor: Tze-Chein Wun
  • Modified tissue plasminogen activator K2K2SP
    Patent number: 5100666
    Abstract: A modified t-PA having improved in vivo half-life is disclosed comprising in sequence a sequence of two K2 kringle regions and a serine protease region SP.
    Type: Grant
    Filed: June 6, 1988
    Date of Patent: March 31, 1992
    Assignee: Monsanto Company
    Inventors: Leslie D. Bell, Ernest J. Mayer, Mark O. Palmier, H. Eser Tolunay, Thomas G. Warren, Tze-Chein Wun
  • Affinity purification of plasminogen activator inhibitor I using a modified urokinase
    Patent number: 5073626
    Abstract: A method of purifying PAI-1 from a biological fluid source, e.g. conditioned media of Hep G2 or HT 1080 cells, containing PAI-1 is disclosed, which comprises subjecting the biological fluid to a modified urokinase affinity absorbent, e.g. anhydrourokinase ligand bound to a CNBr-activated agarose gel or urokinase mutated at amino acid position 356 from Ser to Gly and bound to the gel, and then eluting PAI-1 from said affinity absorbent. A method of stabilizing and/or activating PAI-1 is also disclosed, which comprises complexing PAI-1 with vitronectin.
    Type: Grant
    Filed: June 4, 1990
    Date of Patent: December 17, 1991
    Assignee: Monsanto Company
    Inventor: Tze-Chein Wun
  • Modified tissue plasminogen activator substituted at cysteine-73 and lysine-277
    Patent number: 5037752
    Abstract: A modified tissue plasminogen activator having an improved in vivo half-life characterized in that the normal protein moiety of 527 amino acids is mutated at the site Cys73.fwdarw.Arg and at the site Lys277.fwdarw.Asp.
    Type: Grant
    Filed: April 3, 1989
    Date of Patent: August 6, 1991
    Assignee: Monsanto Company
    Inventors: Leslie D. Bell, Ernest J. Mayer, Mark O. Palmier, H. Eser Tolunay, Thomas G. Warren, Tze-Chein Wun
  • DNA clones of human placental plasminogen activator inhibitor
    Patent number: 5028534
    Abstract: cDNA clones having a base sequence for human placental plasminogen activator inhibitor (PAI-2) have been developed and characterized and the amino acid sequence of the PAI-2 has been determined. The PAI-2 protein has then been expressed in prokaryotic and eukaryotic cells.
    Type: Grant
    Filed: September 15, 1987
    Date of Patent: July 2, 1991
    Assignees: Washington Univ., Monsanto Company
    Inventors: J. Evan Sadler, Tze-Chein Wun
  • DNA clone of human tissue factor inhibitor
    Patent number: 4966852
    Abstract: A cDNA clone having a base sequence for human tissue factor inhibitor (TFI) has been developed and characterized and the amino acid sequence of the TFI has been determined.
    Type: Grant
    Filed: November 23, 1987
    Date of Patent: October 30, 1990
    Assignees: Monsanto Company, Washington University
    Inventors: Tze-Chein Wun, Kuniko K. Kretzmer, George J. Broze, Jr.
  • Tissue plasminogen activator modified by the substitution of Arg for Cys at position 73, methods and pharmaceutical compositions therefor
    Patent number: 4963357
    Abstract: A modified tissue plasminogen activator having an improved in vivo half-life characterized in that the normal protein moiety of 527 amino acids is mutated at the site Cys73.fwdarw.Arg.
    Type: Grant
    Filed: January 29, 1988
    Date of Patent: October 16, 1990
    Assignee: Monsanto Company
    Inventors: Leslie D. Bell, Ernest J. Mayer, Mark O. Palmier, H. Eser Tolunay, Thomas G. Warren, Tze-Chein Wun